Drug utilisation evaluation in patients with osteoarthritis in tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20220408Keywords:
Osteoarthritis, Drug utilization study, NSAID’s, Clinical pharmacistAbstract
Background: The principle aim of our study is to assess the prescribing pattern of drugs used in treatment of osteoarthritis patients.
Methods: A prospective and empirical study was carried out at department of orthopaedics-Shadan teaching and general hospital, for 6 months.
Results: During the study period, a total 120 patients were enrolled, of which 57% were females, 43% were males and common age group was ≥60 years. It was found that 56% of OA patient have history of trauma and 62% of obese individual contribute to occurrence of OA. It was found that subjects developed comorbidities like CV disorders which is 36%. It was found that 63% have OA for a duration of >2 years, 56% had no knowledge about their medications, 59% have co-morbidity, 61% have treatment complexity. NSAID’s, calcium, vitamin D3, glucosamine and chondroitin sulphate were the most frequently prescribed drugs in OA accounting for 50%. It was reported that 55% were adherent to OA medication, adherence to physical activity was 64%, adherence to weight loss was 62%.
Conclusions: Our study manifest that majority of the patients had duration of >2 years of OA. The reasons for the uncontrolled pain was due to absence of awareness about osteoarthritis-related difficulties, drugs, low calcium diet, increased stress, obesity, and advanced age. Continuous health education, patient counselling, information about medication adherence and satisfaction at follow-ups is essential to avoid the problems.
Metrics
References
WHO Essential medicine list. Available at: https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines. Accessed on 20 September 2021.
Robert N. Managed care pharmacy practice. 2nd edition.USA: Jones & Bartlett Learning; 2008.
Dalbeth HN. Oxford Textbook of Osteoarthritis and Crystal Arthropathy. In: Michael D, Bijlsma J, David NA eds. 3rd ed. United Kingdom: Oxford Press;2009:3-4.
Medicine Information. Available at: emedicine. medscape.com/article/330487-overview. Accessed on 20 September 2021.
Creamer P, Hochberg MC. Why does osteoarthritis of the knee hurt--sometimes? Br J Rheumatol. 1997; 36(7):726-8.
Wollheim FA. Serum markers of articular cartilage damage and repair. Rheum Dis Clin North Am. 1999; 25(2):417-32.
Myers SL, Synovial fluid markers in osteoarthritis. Rheum Dis Clin North Am. 1999;25(2):433-49.
Felson DT, Lawrence RC, Dieppe PA. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-46.
DiPiro JT. Pharmacotherapy: A pathophysiologic approach. New York: McGraw-Hill Medical; 2010.
Al-Omari B. Osteoarthritis and management. Orthoped Res J. 2019;5 (5):576-9.
Zhang W, Ouyang H, Dass C. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016;4:15040.
Yusuf E. Pharmacologic and non-pharmacologic treatment of osteoarthritis. Curr Treat Options Rheumatol. 2016;2(2):111-25.
Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarth Cartil. 2020;28(3):242-8.
Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995;38(8):1134-41.
Gupta R, Malhotra A, Malhotra P. Study of prescription pattern of drugs used in the treatment of osteoarthritis in a tertiary care teaching hospital: an observational study. Int J Res Med Sci. 2019;6:985.
Dominick KL, Golightly YM, Bosworth HB. Racial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritis. Ethn Dis. 2005;15(1):116-22.
Downloads
Published
How to Cite
Issue
Section
